Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Grifols Sa ADR (GIKLY)

Grifols Sa ADR (GIKLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.06
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.9700 +8.64%
on 11/13/19
17.3500 unch
on 12/12/19
+2.0600 (+13.47%)
since 10/24/19
3-Month
14.6200 +18.67%
on 09/30/19
17.3500 unch
on 12/12/19
+1.5500 (+9.81%)
since 09/05/19
52-Week
12.6000 +37.70%
on 12/21/18
17.3500 unch
on 12/12/19
+3.4500 (+24.82%)
since 12/06/18

Most Recent Stories

More News
Grifols launches XEMBIFY® (immune globulin subcutaneous human-klhw) 20%, a new Primary Immunodeficiency treatment

BARCELONA , Dec. 12, 2019 /PRNewswire/ --   Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of its latest...

GRFS : 22.77 (+0.18%)
GIKLY : 17.3500 (+2.18%)
Grifols presents its latest Alzheimer's clinical trial data

BARCELONA, Spain , Dec. 6, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, today concluded more than a year of encouraging...

GRFS : 22.77 (+0.18%)
GIKLY : 17.3500 (+2.18%)
Grifols Streamlines Hospital Pharmacy Operations With New KIRO Fill® Technology and PharmacyKeeper Enhancements

BARCELONA, Spain , Dec. 5, 2019 /PRNewswire/ --   Grifols   (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and...

GRFS : 22.77 (+0.18%)
GIKLY : 17.3500 (+2.18%)
GIFOF : 22.8000 (+1.95%)
GIFLF : 34.4500 (+0.76%)
GRF : 7.61 (+0.13%)
Grifols to present latest Alzheimer's clinical trial results

BARCELONA, Spain , Dec. 2, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, will present the final and complete clinical,...

GRFS : 22.77 (+0.18%)
GIKLY : 17.3500 (+2.18%)
Grifols introduces AlphaID™, a free cheek swab to screen for Alpha-1, the most common genetic form of COPD

BARCELONA, Spain , Nov. 7, 2019 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic...

GRFS : 22.77 (+0.18%)
GIKLY : 17.3500 (+2.18%)
Grifols presents additional encouraging Alzheimer's trial results at AAIC

BARCELONA, Spain , July 16, 2019 /PRNewswire/ -- The Grifols Clinical Research team, led by Dr. Antonio Páez, today presented additional results of its AMBAR (Alzheimer Management by Albumin Replacement)...

GRFS : 22.77 (+0.18%)
GIKLY : 17.3500 (+2.18%)
Grifols Selected to Build Its First Intravenous Solutions Manufacturing Line in Africa

BARCELONA, Spain , July 3, 2019 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases,...

GRF : 7.61 (+0.13%)
GRFS : 22.77 (+0.18%)
GIKLY : 17.3500 (+2.18%)
Grifols Announces the Opening of its new Plasma Donor Center in Hinesville, Georgia

GRFS : 22.77 (+0.18%)
GIKLY : 17.3500 (+2.18%)
Grifols donations of blood clotting factor helping people with hemophilia globally

BARCELONA, Spain , April 15, 2019 /PRNewswire/ -- Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its long-term...

GRFS : 22.77 (+0.18%)
GIKLY : 17.3500 (+2.18%)
Grifols 2018 Annual Report on Form 20-F Filed With the SEC on April 5, 2019

GIKLY : 17.3500 (+2.18%)
GRFS : 22.77 (+0.18%)
GIFOF : 22.8000 (+1.95%)
GIFLF : 34.4500 (+0.76%)
GRF : 7.61 (+0.13%)
Trade GIKLY with:

Key Turning Points

2nd Resistance Point 17.3500
1st Resistance Point 17.3500
Last Price 17.3500
1st Support Level 17.3500
2nd Support Level 17.3500

See More

52-Week High 17.3500
Last Price 17.3500
Fibonacci 61.8% 15.5355
Fibonacci 50% 14.9750
Fibonacci 38.2% 14.4145
52-Week Low 12.6000

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar